What are your top takeaways in Gyn Cancers from ESMO 2024?
1 Answers
Mednet Member
Gynecologic Oncology · Legacy Health System
- Ovarian CA (Immunotherapy)
There has been limited success with single agent immunotherapy in ovarian cancer. Three ovarian cancer immunotherapy studies presented at ESMO 2024 are worth noting.
ATHENA-COMBO: Rucaparib +/- Nivo as Maintenance in Newly Diagnosed Ovarian Cancer - ATHENA-COMBO Ph3 Trial
A...